Key result
Novel 9-lncRNA signature identifies acute myocardial infarction with ~67% validation accuracy.
Why the study?
Does a 9-lncRNA expression signature (9LncSigAMI) accurately distinguish acute myocardial infarction patients from healthy controls for early diagnosis?
Case-Control (n=151)
Does a 9-lncRNA expression signature (9LncSigAMI) accurately distinguish acute myocardial infarction patients from healthy controls for early diagnosis?
Identifies and validates a novel 9-lncRNA transcriptional signature (9LncSigAMI) linked to innate immune and inflammatory pathways that can discriminate acute myocardial infarction patients from healthy controls.
Answers are grounded in this paper and cite their sources.
Should not yet inform AMI diagnosis; leaves open prospective validation of 9LncSigAMI.
// Chaoyu Sun 1 , Hao Jiang 2 , Zhiguo Sun 2 , Yifang Gui 3 , Hongyuan Xia 1 1 Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China 2 Department of General Surgery, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang 157011, China 3 The Clinical Laboratory, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang 157011, China Correspondence to: Hongyuan Xia, email: hongyxia@yeah.net Keywords: biomarkers, diagnosis, long non-coding RNAs, myocardial infarction Received: July 06, 2016 Accepted: August 24, 2016 Published: September 13, 2016 ABSTRACT Long non-coding RNAs (lncRNAs) have recently been shown as novel promising diagnostic or prognostic biomarkers for various cancers. However, lncRNA expression patterns and their predictive value in early diagnosis of myocardial infarction (MI) have not been systematically investigated. In our study, we performed a comprehensive analysis of lncRNA expression profiles in MI and found altered lncRNA expression pattern in MI compared to healthy samples. We then constructed a lncRNA-mRNA dysregulation network (DLMCEN) by integrating aberrant lncRNAs, mRNAs and their co-dysregulation relationships, and found that some of mRNAs were previously reported to be involved in cardiovascular disease, suggesting the functional roles of dysregulated lncRNAs in the pathogenesis of MI. Therefore, using support vector machine (SVM) and leave one out cross-validation (LOOCV), we developed a 9-lncRNA signature (termed 9LncSigAMI) from the discovery cohort which could distinguish MI patients from healthy samples with accuracy of 95.96%, sensitivity of 93.88% and specificity of 98%, and validated its predictive power in early diagnosis of MI in another completely independent cohort. Functional analysis demonstrated that these nine lncRNA biomarkers in the 9LncSigAMI may be involved in myocardial innate immune and inflammatory response, and their deregulation may lead to the dysfunction of the inflammatory and immune system contributing to MI recurrence. With prospective validation, the 9LncSigAMI identified by our work will provide additional diagnostic information beyond other known clinical parameters, and increase the understanding of the molecular mechanism underlying the pathogenesis of MI.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2016) conducted a case-control in Acute Myocardial Infarction (n=151). 9-lncRNA diagnostic signature (9LncSigAMI) vs. Healthy control samples was evaluated on Early diagnostic classification of acute myocardial infarction vs healthy controls (Accuracy 95.96%, AUC 0.985 (discovery); Accuracy 67.31%, AUC 0.771 (validation), p=5.431e-12). The 9-lncRNA signature (9LncSigAMI) distinguished acute myocardial infarction patients from healthy controls with 95.96% accuracy in the discovery cohort and 67.31% accuracy in the validation cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: